Two new treatment options using immunotherapy for patients with advanced oesophageal cancer have shown significantly improved long-term survival, according to a study conducted at The Royal Marsden NHS Foundation Trust.

We are joining the National Institute for Health Research in celebrating International Clinical Trials Day 2021 and saying thank you to all of those involved in clinical trials.

Researchers from The Royal Marsden, The Francis Crick Institute, UCL and Cruces University Hospital have found that cells from different parts of kidney tumours behave differently, and surprisingly, cells within the centre of a tumour are the most aggressive and have the highest chance of spreading around the body.

Professor Nicholas Turner has been recognised with a prestigious Fellowship of the Academy of Medical Sciences for his excellence in breast cancer research and outstanding contribution to the field.

Targeting a molecule on the surface of immune cells could offer an exciting new way to treat prostate cancer by reawakening the immune response against it.

A single dose of a Covid-19 vaccine triggers an immune response in around 70 per cent of patients with myeloma – suggesting that it does provide protection against the virus.

Immunotherapy together with an experimental cancer drug could offer a new way of treating some patients with aggressive brain cancers, promising early results from a Phase I trial suggest.

A drug discovered at The Institute of Cancer Research, London that could counteract drug resistance in patients with cancers including acute myeloid leukaemia has entered a phase I clinical trial at The Royal Marsden NHS Foundation Trust.

A combination of three drugs is safe and shows signs of effectiveness in treating some patients with previously treated advanced breast cancer, a clinical trial shows.

Cancers that are resistant to radiotherapy could be rendered susceptible through treatment with immunotherapy, a new study supported by the NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London suggests.